On the public citation graph

https://doi.org/10.2139/ssrn.4658486

0 signed · 58 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/jcb.10661openalex-extracted
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
inferredcites →https://doi.org/10.1002/pros.20753openalex-extracted
Cell‐Surface labeling and internalization by a fluorescent inhibitor of prostate‐specific membrane antigen
inferredcites →https://doi.org/10.1002/pros.20909openalex-extracted
In vitro targeted photodynamic therapy with a pyropheophorbide‐a conjugated inhibitor of prostate‐specific membrane antigen
inferredcites →https://doi.org/10.1002/pros.21164openalex-extracted
Saporin toxin‐conjugated monoclonal antibody targeting prostate‐specific membrane antigen has potent anticancer activity
inferredcites →https://doi.org/10.1002/pros.21221openalex-extracted
Flow cytometric detection of prostate tumor cells using chemoaffinity labels
inferredcites →https://doi.org/10.1002/pros.22575openalex-extracted
PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance
inferredcites →https://doi.org/10.1002/smll.200800972openalex-extracted
Cancer‐Cell‐Phenotype‐Dependent Differential Intracellular Trafficking of Unconjugated Quantum Dots
inferredcites →https://doi.org/10.1007/s003350010240openalex-extracted
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase
inferredcites →https://doi.org/10.1007/s11307-019-01404-8openalex-extracted
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403
inferredcites →https://doi.org/10.1007/s40265-020-01337-5openalex-extracted
Sacituzumab Govitecan: First Approval
inferredcites →https://doi.org/10.1016/j.bios.2005.12.015openalex-extracted
Labeling tumor cells with fluorescent nanocrystal–aptamer bioconjugates
inferredcites →https://doi.org/10.1016/j.bmcl.2010.09.057openalex-extracted
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer
inferredcites →https://doi.org/10.1016/j.bmcl.2011.09.115openalex-extracted
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen
inferredcites →https://doi.org/10.1016/j.bmcl.2012.11.015openalex-extracted
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles
inferredcites →https://doi.org/10.1016/j.canlet.2010.04.003openalex-extracted
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
inferredcites →https://doi.org/10.1016/j.ejpb.2016.04.016openalex-extracted
Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations
inferredcites →https://doi.org/10.1016/j.jfluchem.2013.10.016openalex-extracted
Synthesis and biological activities of fluorinated 10-hydroxycamptothecin and SN38
inferredcites →https://doi.org/10.1016/j.neulet.2005.06.015openalex-extracted
Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography
inferredcites →https://doi.org/10.1016/j.nucmedbio.2015.06.003openalex-extracted
A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer
inferredcites →https://doi.org/10.1016/j.tetlet.2020.151650openalex-extracted
Tunable pH-sensitive 2-carboxybenzyl phosphoramidate cleavable linkers
inferredcites →https://doi.org/10.1016/j.tetlet.2020.152398openalex-extracted
A click-ready pH-triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E
inferredcites →https://doi.org/10.1016/j.urology.2005.03.043openalex-extracted
Future therapies in hormone-refractory prostate cancer
inferredcites →https://doi.org/10.1016/s1078-1439(03)00151-0openalex-extracted
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
inferredcites →https://doi.org/10.1021/ac050312qopenalex-extracted
Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with Cells
inferredcites →https://doi.org/10.1021/ac202001zopenalex-extracted
High Resolution Time-of-Flight Mass Analysis of the Entire Range of Intact Singly-Charged Proteins
inferredcites →https://doi.org/10.1021/acs.bioconjchem.1c00435openalex-extracted
Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells
inferredcites →https://doi.org/10.1021/acs.bioconjchem.6b00422openalex-extracted
Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01850openalex-extracted
Structure–Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer
inferredcites →https://doi.org/10.1021/acs.molpharmaceut.0c00457openalex-extracted
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy
inferredcites →https://doi.org/10.1021/acs.molpharmaceut.7b00315openalex-extracted
Photothermal, Targeting, Theranostic Near-Infrared Nanoagent with SN38 against Colorectal Cancer for Chemothermal Therapy
inferredcites →https://doi.org/10.1021/acsmedchemlett.0c00031openalex-extracted
Folate Receptor Targeting and Cathepsin B‑Sensitive Drug Delivery System for Selective Cancer Cell Death and Imaging
inferredcites →https://doi.org/10.1021/acsmedchemlett.7b00189openalex-extracted
Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole
inferredcites →https://doi.org/10.1021/acsnano.2c09788openalex-extracted
Two-Stage SN38 Release from a Core–Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1021/bc500362nopenalex-extracted
Development of Inhibitor-Directed Enzyme Prodrug Therapy (IDEPT) for Prostate Cancer
inferredcites →https://doi.org/10.1021/bi801883vopenalex-extracted
Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics
inferredcites →https://doi.org/10.1021/ol1002626openalex-extracted
The Synthesis of a c(RGDyK) Targeted SN38 Prodrug with an Indolequinone Structure for Bioreductive Drug Release
inferredcites →https://doi.org/10.1038/bjc.2015.435openalex-extracted
Antibody-drug conjugates—an emerging class of cancer treatment
inferredcites →https://doi.org/10.1038/nbt994openalex-extracted
In vivo cancer targeting and imaging with semiconductor quantum dots
inferredcites →https://doi.org/10.1038/s41598-019-56603-8openalex-extracted
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
inferredcites →https://doi.org/10.1039/9781839165153openalex-extracted
Chemical Linkers in Antibody–Drug Conjugates (ADCs)
inferredcites →https://doi.org/10.1039/c6bm00800copenalex-extracted
Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2690openalex-extracted
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen:In vivoImaging in Experimental Models of Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-2107openalex-extracted
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-3396openalex-extracted
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0191openalex-extracted
In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
inferredcites →https://doi.org/10.1158/1535-7163.mct-22-0160openalex-extracted
Modular Smart Molecules for PSMA-Targeted Chemotherapy
inferredcites →https://doi.org/10.1162/15353500200202109openalex-extracted
11 C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)
inferredcites →https://doi.org/10.1200/jco.2005.05.160openalex-extracted
Phase I Trial of 177 Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
inferredcites →https://doi.org/10.1200/jco.2006.07.8097openalex-extracted
Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors
inferredcites →https://doi.org/10.1615/critrevimmunol.v21.i1-3.160openalex-extracted
A Unique Folate Hydrolase, Prostate-Specific Membrane Antigen (PSMA): A Target For Immunotherapy?
inferredcites →https://doi.org/10.2310/7290.2005.05163openalex-extracted
High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen
inferredcites →https://doi.org/10.2741/a916openalex-extracted
Ins and outs of clinical trials with peptide-based vaccines
inferredcites →https://doi.org/10.2967/jnumed.109.066589openalex-extracted
Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.114.147413openalex-extracted
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
inferredcites →https://doi.org/10.3109/10717544.2014.895069openalex-extracted
Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies
inferredcites →https://doi.org/10.3892/ijo.2011.946openalex-extracted
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium
inferredcites →https://doi.org/10.3892/ijo_00000553openalex-extracted
Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway
inferredcites →https://doi.org/10.7150/thno.18719openalex-extracted
177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.